Javascript must be enabled to continue!
Pancreatic Cysts after Endoscopic Ultrasonography-Guided Ethanol and/or Paclitaxel Ablation Therapy: Another Mimic of Pancreatic Pseudocysts
View through CrossRef
<b><i>Background:</i></b> Endoscopic ultrasound-guided ablation (EUS-A) therapy is a minimally invasive procedure for pancreatic-cystic tumors in patients with preoperative comorbidities or in patients who are not indicated for surgical resection. However, histopathologic characteristics of pancreatic cysts after ablation have not been well-elucidated. <b><i>Methods:</i></b> Here, we analyzed pathological findings of 12 surgically resected pancreatic cysts after EUS-A with ethanol and/or paclitaxel injection. <b><i>Results:</i></b> Mean patient age was 49.8 ± 13.6 years with a 0.3 male/female ratio. Clinical impression before EUS-A was predominantly mucinous cystic neoplasms. Mean cyst size before and after ablation therapy was similar (3.7 ± 1.0 cm vs. 3.4 ± 1.6 cm; <i>p</i> = 0.139). Median duration from EUS-A to surgical resection was 18 (range, 1–59) months. Mean percentage of the residual neoplastic lining epithelial cells were 23.1 ± 37.0%. Of the resected cysts, 8 cases (67%) showed no/minimal (<5%) residual lining epithelia, while the remaining 4 cases (33%) showed a wide range of residual mucinous epithelia (20–90%). Ovarian-type stroma was noted in 5 cases (42%). Other histologic features included histiocytic aggregation (67%), stromal hyalinization (67%), diffuse egg shell-like calcification along the cystic wall (58%), and fat necrosis (8%). <b><i>Conclusion:</i></b> Above all, diffuse egg shell-like calcification along the pancreatic cystic walls with residual lining epithelia and/or ovarian-type stroma were characteristics of pancreatic cysts after EUS-A. Therefore, understanding these histologic features will be helpful for precise pathological diagnosis of pancreatic cystic tumor after EUS-A, even without knowing the patient’s history of EUS-A.
Title: Pancreatic Cysts after Endoscopic Ultrasonography-Guided Ethanol and/or Paclitaxel Ablation Therapy: Another Mimic of Pancreatic Pseudocysts
Description:
<b><i>Background:</i></b> Endoscopic ultrasound-guided ablation (EUS-A) therapy is a minimally invasive procedure for pancreatic-cystic tumors in patients with preoperative comorbidities or in patients who are not indicated for surgical resection.
However, histopathologic characteristics of pancreatic cysts after ablation have not been well-elucidated.
<b><i>Methods:</i></b> Here, we analyzed pathological findings of 12 surgically resected pancreatic cysts after EUS-A with ethanol and/or paclitaxel injection.
<b><i>Results:</i></b> Mean patient age was 49.
8 ± 13.
6 years with a 0.
3 male/female ratio.
Clinical impression before EUS-A was predominantly mucinous cystic neoplasms.
Mean cyst size before and after ablation therapy was similar (3.
7 ± 1.
0 cm vs.
3.
4 ± 1.
6 cm; <i>p</i> = 0.
139).
Median duration from EUS-A to surgical resection was 18 (range, 1–59) months.
Mean percentage of the residual neoplastic lining epithelial cells were 23.
1 ± 37.
0%.
Of the resected cysts, 8 cases (67%) showed no/minimal (<5%) residual lining epithelia, while the remaining 4 cases (33%) showed a wide range of residual mucinous epithelia (20–90%).
Ovarian-type stroma was noted in 5 cases (42%).
Other histologic features included histiocytic aggregation (67%), stromal hyalinization (67%), diffuse egg shell-like calcification along the cystic wall (58%), and fat necrosis (8%).
<b><i>Conclusion:</i></b> Above all, diffuse egg shell-like calcification along the pancreatic cystic walls with residual lining epithelia and/or ovarian-type stroma were characteristics of pancreatic cysts after EUS-A.
Therefore, understanding these histologic features will be helpful for precise pathological diagnosis of pancreatic cystic tumor after EUS-A, even without knowing the patient’s history of EUS-A.
Related Results
Abstract B8: Caveolae-mediated endocytosis is critical for tumor cell response to nab-paclitaxel
Abstract B8: Caveolae-mediated endocytosis is critical for tumor cell response to nab-paclitaxel
Abstract
INTRODUCTION:
Pancreatic cancer is the fourth leading cause of cancer-related deaths in the United States and is typified by poor outcomes. G...
Abstract B14: A novel strategy for the treatment of melanoma
Abstract B14: A novel strategy for the treatment of melanoma
Abstract
Introduction: Approximately 76,000 individuals are diagnosed with melanoma, and about 9,000 die as a result of the disease each year in the United States. E...
Microwave Ablation with or Without Chemotherapy in Management of Non-Small Cell Lung Cancer: A Systematic Review
Microwave Ablation with or Without Chemotherapy in Management of Non-Small Cell Lung Cancer: A Systematic Review
Abstract
Introduction
Microwave ablation (MWA) has emerged as a minimally invasive treatment for patients with inoperable non-small cell lung cancer (NSCLC). However, whether it i...
Current Perspectives on Cystic Echinococcosis: A Systematic Review
Current Perspectives on Cystic Echinococcosis: A Systematic Review
Abstract
Introduction: Hydatidosis, a zoonotic disease caused by the larval stage of Echinococcus granulosus, is a significant public health concern with notable economic impact. I...
Abstract 1071: Efficacy of targeted osmotic lysis using pulsed electric field stimulation compared to paclitaxel for treating murine, triple-negative breast carcinoma
Abstract 1071: Efficacy of targeted osmotic lysis using pulsed electric field stimulation compared to paclitaxel for treating murine, triple-negative breast carcinoma
Abstract
Targeted osmotic lysis (TOL), the concurrent stimulation of voltage-gated sodium channels (VGSCs) and blockade of Na+ pumps, kills up to 100% of highly mali...
Phase I Dose-Finding and Pharmacokinetic Study of Paclitaxel and Carboplatin With Oral Valspodar in Patients With Advanced Solid Tumors
Phase I Dose-Finding and Pharmacokinetic Study of Paclitaxel and Carboplatin With Oral Valspodar in Patients With Advanced Solid Tumors
PURPOSE: To evaluate the maximum-tolerated dose (MTD), dose-limiting toxicities (DLTs), and pharmacokinetic (PK) profile of paclitaxel and carboplatin when administered every 3 wee...
A Taxane Total Cost of Care Analysis in Metastatic Breast Cancer: Results of Private Payor Claims Data.
A Taxane Total Cost of Care Analysis in Metastatic Breast Cancer: Results of Private Payor Claims Data.
Abstract
Background: It has been estimated that over $8 billion is spent annually on the management of breast cancer in the US. The taxane chemotherapeutic agents ar...
Abstract IA-08: Clinical advances in pancreas adenocarcinoma
Abstract IA-08: Clinical advances in pancreas adenocarcinoma
Abstract
Pancreatic adenocarcinoma (PDAC) remains one of the most lethal cancers today and is expected to be the second cause of cancer death in the coming decade. M...

